✦ LIBER ✦

AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer

✍ Scribed by Furukawa, T; Kanai, N; Shiwaku, H O; Soga, N; Uehara, A; Horii, A

Book ID: 110070514
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 329 KB
Volume: 25
Category: Article
ISSN: 0950-9232
DOI: 10.1038/sj.onc.1209494

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SHP2 is a downstream target of ZAP70 to

SHP2 is a downstream target of ZAP70 to regulate JAK1/STAT3 and ERK signaling pathways in mouse embryonic stem cells

✍ Young Cha; Kyung-Soon Park 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 738 KB

Downstream Targets of Dopamine Receptor

Downstream Targets of Dopamine Receptor D3 Activation in the Mouse Pancreatic β-Cells

✍ Ustione, Alessandro; Jacobson, David A.; Piston, David W. 📂 Article 📅 2014 🏛 Biophysical Society 🌐 English ⚖ 67 KB

The Wnt antagonist DICKKOPF-1 gene is a

The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer

✍ González-Sancho, José Manuel; Aguilera, Oscar; García, José Miguel; Pendás-Franc 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 176 KB

ERK, and its downstream target, est-1, a

ERK, and its downstream target, est-1, are involved in the 1,25(OH)2D3-induced inhibition of cell growth and stimulation of apoptosis in Caco-2 cells

✍ Chen, Anping; Bissonnette, Marc; Sitrin, Michael D.; Brasitus, Thomas A. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Interleukin-2 is one of the targets of 1

Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system

✍ Candace J Bemiss; Brett D Mahon; Adam Henry; Veronika Weaver; Margherita T Canto 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 105 KB

p38 MAPK, but not ERK1/2, is critically

p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4

✍ Haitian Quan; Yongping Xu; Liguang Lou 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 739 KB

## Abstract Combretastatin A4 (CA4) is a novel vascular disrupting agent that has promising clinical efficacy because of its ability to inhibit microtubule assembly and subsequently disrupt tumor blood flow. In this study, we demonstrate that mitogen‐activated protein kinases (MAPKs) are critically